{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:13:38Z","timestamp":1778933618801,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Asia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jacasi.2025.12.014","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T05:06:03Z","timestamp":1770440763000},"page":"724-732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ambrisentan for Early-Stage Low-Risk Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-8556","authenticated-orcid":false,"given":"Jun-yan","family":"Kan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-de","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fen-ling","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guan-wen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Du-jiang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3887-952X","authenticated-orcid":false,"given":"Shao-liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jacasi.2025.12.014_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-023-00486-7","article-title":"Pulmonary hypertension","volume":"10","author":"Mocumbi","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jacasi.2025.12.014_bib2","first-page":"2493","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension","author":"Gali","year":"2009","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacasi.2025.12.014_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"issue":"13","key":"10.1016\/j.jacasi.2025.12.014_bib4","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/CIRCULATIONAHA.115.020207","article-title":"Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: Insights from the Veterans Affairs clinical assessment, reporting, and tracking program","volume":"133","author":"Maron","year":"2016","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jacasi.2025.12.014_bib5","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1001\/jamacardio.2017.3882","article-title":"Prognostic effect and longitudinal hemodynamic assessment of borderline pulmonary hypertension","volume":"2","author":"Assad","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacasi.2025.12.014_bib6","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacasi.2025.12.014_bib7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension","volume":"46","author":"Gali\u00e9","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2025.12.014_bib8","first-page":"265","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension","author":"Casserly","year":"2008","journal-title":"Drug Des Devel Ther"},{"issue":"21","key":"10.1016\/j.jacasi.2025.12.014_bib9","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","article-title":"Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension","volume":"54","author":"Oudiz","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacasi.2025.12.014_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13075-019-1981-0","article-title":"Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: A randomized, controlled, double-blind, parallel group study (EDITA study)","volume":"21","author":"Pan","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.jacasi.2025.12.014_bib11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13075-024-03363-0","article-title":"Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study","volume":"26","author":"Xanthouli","year":"2024","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.jacasi.2025.12.014_bib12","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/art.33460","article-title":"Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure","volume":"64","author":"Kovacs","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.jacasi.2025.12.014_bib13","first-page":"00466","article-title":"Association of PH-targeted therapy and survival in precapillary PH with mPAP between 21 and 24 mmHg","volume":"11","author":"Yogeswaran","year":"2025","journal-title":"ERJ Open Res"},{"issue":"408","key":"10.1016\/j.jacasi.2025.12.014_bib14","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/01621459.1989.10478873","article-title":"Regression analysis of multivariate incomplete failure time data by modeling marginal distributions","volume":"84","author":"Wei","year":"1989","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"10.1016\/j.jacasi.2025.12.014_bib15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12890-017-0523-2","article-title":"Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis-an interim analysis of results from a prospective, single-center, randomized, parallel-group study","volume":"17","author":"Tanaka","year":"2017","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jacasi.2025.12.014_bib16","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-2600(23)00264-3","article-title":"Treatment of pulmonary arterial hypertension: recent progress and a look to the future","author":"Humbert","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jacasi.2025.12.014_bib17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.chest.2020.08.2069","article-title":"Development and validation of an abridged version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension","volume":"159","author":"Benza","year":"2021","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.jacasi.2025.12.014_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cardfail.2009.09.008","article-title":"Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension","volume":"16","author":"Blalock","year":"2010","journal-title":"J Card Fail"},{"issue":"9","key":"10.1016\/j.jacasi.2025.12.014_bib19","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jacasi.2025.12.014_bib20","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1164\/rccm.202009-3698OC","article-title":"Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension","volume":"204","author":"Boucly","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jacasi.2025.12.014_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01095-2024","article-title":"Pathology and pathobiology of pulmonary hypertension: current insights and future directions","volume":"64","author":"Guignabert","year":"2024","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jacasi.2025.12.014_bib22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","article-title":"Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?","volume":"114","author":"Stewart","year":"1991","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.jacasi.2025.12.014_bib23","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1164\/rccm.201501-0196OC","article-title":"Endothelin-1 pathway polymorphisms and outcomes in pulmonary arterial hypertension","volume":"192","author":"Benza","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"20","key":"10.1016\/j.jacasi.2025.12.014_bib24","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.jacc.2019.02.067","article-title":"Immunotherapy of endothelin-1 receptor type A for pulmonary arterial hypertension","volume":"73","author":"Dai","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["JACC: Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277237472600027X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277237472600027X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:43:28Z","timestamp":1778931808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S277237472600027X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S277237472600027X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacasi.2025.12.014","relation":{},"ISSN":["2772-3747"],"issn-type":[{"value":"2772-3747","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ambrisentan for Early-Stage Low-Risk Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"JACC: Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacasi.2025.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}